Pharmacotherapy of schizophrenia is associated with the stressful side effects. Muscle rigidity causes distress, discomfort and poor compliance. The aim of the study was to determine the relationship between plasma hormones (cortisol and prolactin/PRL) and muscle rigidity in female schizophrenic patients treated with olanzapine or fluphenazine. In a randomized, double-blind 22-weeks study, 12 patients were treated with olanzapine (5-20 mg/day) and 10 patients received fluphenazine (6-21 mg/day). Treatment with olanzapine moderately decreased, while treatment with fluphenazine significantly increased plasma cortisol levels and muscle rigidity. The marked and moderate increase in plasma PRL levels were found in patients treated with fluphenazine and olanzapine, respectively. The results suggested that olanzapine induced moderate neuroendocrine effects and a reduction in rigidity as compared to fluphenazine treatment.
Introduction
The pharmacotherapy of schizophrenia (Kane, 2001 ) is often associated with the extrapyramidal side effects (EPS) related to the blockade of dopamine D 2 receptors in the basal ganglia (Crocker and Hemsley, 2001 ) and disturbance of dopaminergic and serotonergic/cholinergic systems. Muscle rigidity and other EPS cause distress, discomfort and poor compliance. Stress hormones prolactin (PRL) and cortisol are related to distress response (Jakovljevic et al., 1991; Tandon and Halbreich, 2003) . Olanzapine is an atypical antipsychotic of the thienobenzodiazepine class. New antipsychotics induce a moderate blockade of D 2 receptors and generate a more subtle functional motor impairment and better treatment response (Putzhammer et al., 2005) than conventional antipsychotics, like fluphenazine. Fluphenazine reduces psychotic symptoms, but induces different side effects (Mortimer, 1994) due to its action achieved via D 1 and D 2 receptors (Coirini et al., 1997; Meltzer and Nash, 1991) .
Since olanzapine and fluphenazine differ in their side effects profile and clinical efficacy (Dossenbach et al., 2004) , our hypothesis was that olanzapine and fluphenazine would differently affect plasma cortisol, PRL and muscle rigidity. The aim of the present study was to determine, in the smaller group of female schizophrenic patients extracted from the previous multicentric double blind study (Dossenbach et al., 2004) , the effects of olanzapine or fluphenazine on plasma PRL and cortisol levels, and muscle rigidity after long term (22-weeks) treatment. 
